由雄激素受体交换活化域和小分子药物形成的共价添加物仍然是无序的
Jiaqi Zhu1, Paul J Robustelli1
1Department of Chemistry, Dartmouth College, Hanover, NH, USA.
bioRxiv : the preprint server for biology
|November 28, 2024
概括
向雄激素受体交换活化域的小分子形成共价添加物,改变蛋白质结构. 分子动力学模拟显示,这些附加物稳定了崩的螺旋形状,有助于开发前列腺癌的强效抑制剂.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 计算生物学 计算生物学
背景情况:
- 内在无序蛋白质 (IDP) 与各种人类疾病有关.
- 针对雄激素受体 (AR) 交换活化域的小分子正在进行针对割抵抗性前列腺癌的临床试验.
- 这些分子与AR氨酸氨酸残留物形成共价添加物,但它们的结构影响尚不清楚.
研究的目的:
- 调查小分子对共价变异如何影响内在无序的AR交换活化域的构造组合.
- 为了提供对小分子和IDPs之间形成的共价 adducts 的原子详细理解.
主要方法:
- 用全原子分子动力学 (MD) 计算机模拟来建模EPI-002和EPI-7170的共价添加物与AR交换活化域.
- 模拟比较了共价添加物与非共价连接物结合状态的构造组合.
主要成果:
- EPI-002和EPI-7170的共价附着导致异质和无序的形状组合.
- 与非共价模拟相比,共价 adducts 显示了与非共价模拟相比,崩的螺旋式 AR 交换活化域形状的增加.
- 确定了稳定这些崩形状的特定蛋白质-连接体相互作用网络.
结论:
- 协价性修改显著改变了AR交换活化域的结构格局.
- 这些发现提供了对向IDP的共价抑制剂的作用机制的见解.
- 这项研究提出了设计更有效的共价抑制剂的策略,用于内在无序的蛋白质标.
更多相关视频
相关概念视频
Drug-Receptor Bonds
2.7K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.7K
Drug-Receptor Interactions
5.0K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.0K
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
Assembly of Signaling Complexes
5.7K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
5.7K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K


